SYNERGY™

Everolimus-Eluting Platinum Chromium Coronary Stent System

Early Healing

Studying DAPT

Clinical Outcomes

Operational Efficiency

Overview

Clinical Program and Research

Real-World Studies

Leading in Complex Patients

Real-World Studies Demonstrate Low Event Rates for the SYNERGY Bioabsorbable Polymer (BP) Stent

The SYNERGY BP Stent demonstrated the numerically lowest stent thrombosis rates compared to other DES, despite being used in patients with more complex disease.¹ The SCAAR registry is a national, 20-hospital registry of data relating to stent performance in Sweden.

Lowest stent thrombosis rate compared to newer generation DES (n-DES) despite use in patients with statistically more Class B2/C Lesions, Diabetes, Prior PCI, and 3VD.¹

Fast Facts Sign Up

Indications, Safety, and Warnings

Frequently Asked Questions

Request a Sales Rep

Cumulative Definite ST Rates at 1-Year¹

Baseline Clinical Characteristics^1*

*Some patients in the SCAAR study were treated for either Left Main, CTO or multi-vessel disease but did not show statistical significance. The safety and efficacy of the SYNERGY BP Stent for those uses has not been established. A total of 7,886 of Synergy stents and 64,429 other n-DES (BioMatrix, N51,953; Orsiro, N54,946; Promus Element Plus, N5 2,543; Promus Premier, N5 20,414; Xience Xpedition, N5 7,971, Resolute/Resolute Integrity, N519,021; Ultimaster, N51,156; Resolute Onyx, N56,425) were implanted in 42,357 procedures.

In addition, a single-arm study of SYNERGY BP Stent reported 0% stent thrombosis and 1.2% target vessel revascularization in a leading complex PCI center in Belfast, Ireland at 1-year.²

Retrospective Analysis, August 2013 – February 2016²*

We are continuing to pursue clinical evidence of patients in real-world studies through our Investigator Sponsored Research program. Learn more about our Clinical Trial Program